Flamel Technologies S.A. (ADR) (NASDAQ:FLML)
CAPS Rating:
A biopharmaceutical company principally engaged in the development of two unique polymer-based drug delivery technologies for the improvement of medical applications.
RSS Headlines
Fool UK
Recs
I've had success betting on Flamel several times before, despite my difficulty understanding their platform and collaborations. I'm seeing the share price dip to almost two year lows despite what appears to be increasing licensing revenue so I'm back on the green thumb.